Model N to Host Life Sciences Commercial and Pricing Innovation Forum in Vienna, Austria
Model N , Inc. (NYSE:MODN), the leading provider of cloud-based revenue management solutions to life sciences, technology and manufacturing companies, today announced it will host the Commercial and Pricing Innovation Forum on October 10-12, 2017, at the Palais Hansen Kempinski in Vienna, Austria. The Forum is designed to drive innovation among thought leaders from industry experts and pharmaceutical, medical device and technology companies.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170925006556/en/
“The Life Sciences Commercial and Pricing Innovation Forum is designed to enable global pricing leaders to share best practices and to drive further innovation,” said Zack Rinat, founder, executive chairman & CEO of Model N. “We are excited to host this Forum to paint the role of Cloud technology in driving end-to-end pricing, tendering and market access.”
The Forum will bring together over 100 pharmaceutical and medical devices executives from around the globe to discuss emerging commercial-wide trends, recurring challenges faced by the industry and best practices in global pricing, tender and revenue management.
“Tender planning is top of mind for commercial and pricing teams in Life Sciences,” said Roman Irsiegler, senior marketing manager biosimilars at Pfizer. “I am delighted to join a panel on tender management during this forum, where I will zoom in on Biosimilars and present the perspective of a mature and sophisticated market where tender and contracts are essential to success.”
The two-day conference includes exclusive business cases, workshops and user discussion groups that will deliver actionable insights for pharmaceutical and medical devices executives involved with global pricing and commercial improvement programs.
- Global Pricing Strategy Throughout the Product Life Cycle
- Innovative Contracting Models : pitfalls and critical success factors in various markets
- Tender Management: the current state of Tendering in medical devices and pharmaceuticals, use of public data, Tender Planning, etc.
- Market Access strategies in Emerging Markets : strategies for sustainable market access
- Value-Based Health Care : enrich the understanding of value-based healthcare, its definition, barriers and opportunities
- Sales Approach Transformation : from product to solution sales
About Model N
Model N is the leader in Revenue Management solutions. Driving mission critical business processes such as configure, price and quote (CPQ), contract and rebate management, business intelligence, and regulatory compliance, Model N solutions transform the revenue lifecycle from a series of disjointed operations into a strategic end-to-end process. With deep industry expertise, Model N supports the complex business needs of the world’s leading brands in life sciences, technology and manufacturing across more than 100 countries, including Johnson & Johnson, AstraZeneca, Boston Scientific, Novartis, Microchip Technology and ON Semiconductor. For more information, visit www.modeln.com .
Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.
Model N, Inc.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
CA-EDGEWATER-NETWORKS20.10.2017 23:02 | pressemeddelelse
Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 2017
VA-CTA20.10.2017 17:10 | pressemeddelelse
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris
PA-WESTINGHOUSE-ELECTRIC20.10.2017 14:17 | pressemeddelelse
Westinghouse Receives Regulatory Approval for Analysis Methodologies
CA-GILEAD-SCIENCES20.10.2017 14:05 | pressemeddelelse
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®
TX-SCHLUMBERGER-LIMITED20.10.2017 13:02 | pressemeddelelse
Schlumberger Announces Third-Quarter 2017 Results
SP3H20.10.2017 12:49 | pressemeddelelse
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum